EA200200417A1 - Фармацевтически активные производные сульфонамида - Google Patents

Фармацевтически активные производные сульфонамида

Info

Publication number
EA200200417A1
EA200200417A1 EA200200417A EA200200417A EA200200417A1 EA 200200417 A1 EA200200417 A1 EA 200200417A1 EA 200200417 A EA200200417 A EA 200200417A EA 200200417 A EA200200417 A EA 200200417A EA 200200417 A1 EA200200417 A1 EA 200200417A1
Authority
EA
Eurasian Patent Office
Prior art keywords
sulfonamide
sulfonamide derivatives
formula
present
substituted
Prior art date
Application number
EA200200417A
Other languages
English (en)
Other versions
EA005368B1 (ru
Inventor
Стефен Аркинстолл
Серж Алази
Деннис Черч
Монтсеррат Камр
Томас Рюкле
Жан-Пьер Готтелан
Марко Бьямонте
Original Assignee
Апплайд Резеч Системз Арс Холдинг Н.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Апплайд Резеч Системз Арс Холдинг Н.В. filed Critical Апплайд Резеч Системз Арс Холдинг Н.В.
Publication of EA200200417A1 publication Critical patent/EA200200417A1/ru
Publication of EA005368B1 publication Critical patent/EA005368B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Настоящее изобретение относится к производным сульфонамида формулы (I), в частности к их применению в качестве фармацевтически активных соединений, а также к фармацевтическим композициям, содержащим такие производные сульфонамида. Указанные производные сульфонамида являются эффективными модуляторами путей передачи сигналов JNK, в частности они являются эффективными и избирательными ингибиторами JNK2 и 3. Настоящее изобретение далее относится к новым производным сульфонамида, а также к способам их получения. К соединениям формулы (I) по настоящему изобретению, являющимся приемлемыми фармацевтическими средствами, относятся такие соединения, в которых Arи Arнезависимо означают замещенные или незамещенные арильные или гетероарильные группы, Х означает О или S, предпочтительно О; Rозначает водород или C-С-алкильную группу либо Rобразует замещенное или незамещенное 5-6-членное насыщенное или ненасыщенное кольцо с Ar; n означает целое число от 0 до 5, предпочтительно 1-3 и наиболее предпочтительно 1; Y в формуле (I) означает незамещенный или замещенный 4-12-членный насыщенный циклический или бициклический алкил, содержащий, по крайней мере, один атом азота, причем один атом азота в указанном кольце образует связь с сульфонильной группой формулы (I), создающую таким образом сульфонамид.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200200417A 1999-09-28 2000-09-28 Фармацевтически активные производные сульфонамида EA005368B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99810869A EP1088821A1 (en) 1999-09-28 1999-09-28 Pharmaceutically active sulfonamide derivatives
PCT/IB2000/001380 WO2001023378A1 (en) 1999-09-28 2000-09-28 Pharmaceutically active sulfonamide derivatives

Publications (2)

Publication Number Publication Date
EA200200417A1 true EA200200417A1 (ru) 2002-10-31
EA005368B1 EA005368B1 (ru) 2005-02-24

Family

ID=8243049

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200200417A EA005368B1 (ru) 1999-09-28 2000-09-28 Фармацевтически активные производные сульфонамида

Country Status (30)

Country Link
US (1) US8012995B1 (ru)
EP (2) EP1088821A1 (ru)
JP (2) JP5015397B2 (ru)
KR (1) KR100827533B1 (ru)
CN (1) CN1189467C (ru)
AR (1) AR031531A1 (ru)
AT (1) ATE309998T1 (ru)
AU (1) AU777708B2 (ru)
BG (1) BG65797B1 (ru)
BR (1) BR0014641A (ru)
CA (1) CA2379575C (ru)
CZ (1) CZ2002880A3 (ru)
DE (1) DE60024115T2 (ru)
DK (1) DK1218374T3 (ru)
EA (1) EA005368B1 (ru)
EE (1) EE05109B1 (ru)
ES (1) ES2248114T3 (ru)
HK (1) HK1048306B (ru)
HU (1) HUP0203312A3 (ru)
IL (2) IL148876A0 (ru)
MX (1) MXPA02003199A (ru)
NO (1) NO324792B1 (ru)
NZ (1) NZ517424A (ru)
PL (1) PL212237B1 (ru)
SI (1) SI1218374T1 (ru)
SK (1) SK287058B6 (ru)
TR (1) TR200200789T2 (ru)
UA (1) UA74796C2 (ru)
WO (1) WO2001023378A1 (ru)
ZA (1) ZA200201509B (ru)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1088821A1 (en) * 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonamide derivatives
EP1088822A1 (en) 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonyl hydrazide derivatives
EP1193268A1 (en) * 2000-09-27 2002-04-03 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonamide derivatives bearing both lipophilic and ionisable moieties as inhibitors of protein Junkinases
EP1193256A1 (en) * 2000-09-27 2002-04-03 Applied Research Systems ARS Holding N.V. Pharmaceutically active benzsulfonamide derivatives as inhibitors of JNK proteins
EP1193267A1 (en) * 2000-09-27 2002-04-03 Applied Research Systems ARS Holding N.V. Pharmaceutically active hydrophilic sulfonamide derivatives as inhibitors of protein JunKinases
NZ526213A (en) * 2000-12-13 2005-05-27 Wyeth Corp Heterocyclic sulfonamide inhibitors of beta amyloid production
US6657070B2 (en) 2000-12-13 2003-12-02 Wyeth Production of chirally pure α-amino acids and N-sulfonyl α-amino acids
DE60234510D1 (de) 2001-04-16 2010-01-07 Eisai R&D Man Co Ltd 1h-indazolverbindungen die jnk hemmen
AU2002331253B2 (en) * 2001-07-23 2008-04-03 Laboratoires Serono Sa Arylsulfonamide derivatives as C-JUN-N-terminal kinases (JNK'S) inhibitors
PA8557501A1 (es) 2001-11-12 2003-06-30 Pfizer Prod Inc Benzamida, heteroarilamida y amidas inversas
WO2003042190A1 (en) 2001-11-12 2003-05-22 Pfizer Products Inc. N-alkyl-adamantyl derivatives as p2x7-receptor antagonists
KR20050004214A (ko) 2002-05-31 2005-01-12 에자이 가부시키가이샤 피라졸 화합물 및 이것을 포함하여 이루어지는 의약 조성물
CA2486581A1 (en) 2002-06-11 2003-12-18 Wyeth Substituted phenylsulfonamide inhibitors of beta amyloid production
PA8591801A1 (es) 2002-12-31 2004-07-26 Pfizer Prod Inc Inhibidores benzamidicos del receptor p2x7.
US7071223B1 (en) 2002-12-31 2006-07-04 Pfizer, Inc. Benzamide inhibitors of the P2X7 receptor
AU2004221812B2 (en) 2003-03-19 2010-02-18 Exelixis Inc. Tie-2 modulators and methods of use
CN101274926A (zh) 2003-03-31 2008-10-01 惠氏公司 β淀粉样蛋白生成抑制剂含氟和三氟烷基杂环磺酰胺及其衍生物
AU2004271741A1 (en) * 2003-09-12 2005-03-24 Laboratoires Serono Sa Sulfonamide derivatives for the treatment of diabetes
WO2005073198A1 (en) 2004-01-16 2005-08-11 Wyeth Heterocyclic sulfonamide inhibitors of beta amyloid production containing an azole
WO2005074921A1 (en) * 2004-02-09 2005-08-18 University Of Zurich Treatment of atherosclerosis
CN1660811A (zh) * 2004-02-27 2005-08-31 中国科学院上海药物研究所 1，4－二取代苯类化合物及其制备方法和用途
WO2005118543A1 (ja) * 2004-06-03 2005-12-15 Ono Pharmaceutical Co., Ltd. キナーゼ阻害薬およびその用途
BRPI0512781A (pt) 2004-06-29 2008-04-08 Pfizer Prod Inc método para preparação de derivados de 5-{4-(2-hidroxi-propil)-3,5-dioxo-4,5-diidro-3h-[1,2,4]tria zin-2-il}-benzamida através da desproteção dos precursores de protetores de hidroxila
US20060094753A1 (en) 2004-10-29 2006-05-04 Alcon, Inc. Use of inhibitors of Jun N-terminal kinases for the treatment of glaucomatous retinopathy and ocular diseases
US7803824B2 (en) 2004-10-29 2010-09-28 Alcon, Inc. Use of inhibitors of Jun N-terminal kinases to treat glaucoma
US20060223807A1 (en) 2005-03-29 2006-10-05 University Of Massachusetts Medical School, A Massachusetts Corporation Therapeutic methods for type I diabetes
AU2011265521B8 (en) * 2005-07-15 2014-05-22 Merck Serono Sa JNK inhibitors for the treatment of endometreosis
BRPI0613042A2 (pt) 2005-07-15 2010-12-14 Serono Lab inibidores de jnk para o tratamento de endometriose
KR20080044836A (ko) 2005-07-15 2008-05-21 라보라뚜와르 세로노 에스. 에이. 자궁내막증 치료용 ｊｎｋ 억제제
US9598669B2 (en) 2005-12-29 2017-03-21 Anthrogenesis Corporation Composition for collecting placental stem cells and methods of using the composition
WO2007141224A2 (en) * 2006-06-02 2007-12-13 Laboratoires Serono Sa Jnk inhibitors for treatment of skin diseases
WO2011060321A1 (en) 2009-11-16 2011-05-19 Chdi, Inc. Transglutaminase tg2 inhibitors, pharmaceutical compositions, and methods of use thereof
US8889716B2 (en) 2011-05-10 2014-11-18 Chdi Foundation, Inc. Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1706174A3 (ru) * 1989-02-08 1995-10-10 Институт биохимии Литовской АН N-замещенные 5-фталимидонафталин-1-сульфамиды в качестве полупродуктов для получения n-замещенных аминонафталинсульфамидов
EP0594593A1 (en) 1990-03-15 1994-05-04 PHARMACIA & UPJOHN COMPANY Therapeutically useful heterocyclic indole compounds
US5106983A (en) 1990-04-30 1992-04-21 The United States Of America As Represented By The Secretary Of The Army Process of making carfentanil and related analgesics
US5576313A (en) 1994-08-29 1996-11-19 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5684013A (en) * 1995-03-24 1997-11-04 Schering Corporation Tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
US6011029A (en) * 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
EP0889876B1 (en) * 1996-03-29 2001-07-25 G.D. SEARLE & CO. Meta-substituted phenylene sulphonamide derivatives
CN1159292C (zh) * 1996-05-31 2004-07-28 法玛西雅厄普约翰美国公司 用作选择性多巴胺d3配体的芳基取代的环胺类化合物
US6020357A (en) * 1996-12-23 2000-02-01 Dupont Pharmaceuticals Company Nitrogen containing heteroaromatics as factor Xa inhibitors
US6043083A (en) 1997-04-28 2000-03-28 Davis; Roger J. Inhibitors of the JNK signal transduction pathway and methods of use
EP1001764A4 (en) * 1997-05-29 2005-08-24 Merck & Co Inc Heterocyclic amides as cell adhesion inhibitors
DE19743435A1 (de) * 1997-10-01 1999-04-08 Merck Patent Gmbh Benzamidinderivate
GB9721437D0 (en) * 1997-10-10 1997-12-10 Glaxo Group Ltd Heteroaromatic compounds and their use in medicine
EP1144381A2 (en) * 1998-11-25 2001-10-17 MERCK PATENT GmbH Substituted benzo[de]isoquinoline-1,3-diones
ES2270867T3 (es) * 1999-09-23 2007-04-16 Astrazeneca Ab Compuestos de quinazolina terapeuticos.
EP1088821A1 (en) * 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonamide derivatives
EP1088815A1 (en) * 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonyl amino acid derivatives
EP1088822A1 (en) 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonyl hydrazide derivatives
US6506901B2 (en) * 2000-07-17 2003-01-14 Wyeth Substituted 2-(S)-hydroxy-3-(piperidin-4-yl-methylamino)-propyl ethers and substituted 2-aryl-2-(R)-hydroxy-1-(piperidin-4-yl-methyl)-ethylamine β-3 adrenergic receptor agonists

Also Published As

Publication number Publication date
PL354169A1 (en) 2003-12-29
EP1218374A1 (en) 2002-07-03
EA005368B1 (ru) 2005-02-24
MXPA02003199A (es) 2002-10-31
BG65797B1 (bg) 2009-12-31
AU7307400A (en) 2001-04-30
NO20021530D0 (no) 2002-03-26
HUP0203312A2 (hu) 2003-01-28
HK1048306A1 (en) 2003-03-28
KR100827533B1 (ko) 2008-05-06
ES2248114T3 (es) 2006-03-16
DK1218374T3 (da) 2005-12-27
SK5802002A3 (en) 2002-08-06
NO20021530L (no) 2002-03-26
EP1218374B1 (en) 2005-11-16
CA2379575A1 (en) 2001-04-05
SI1218374T1 (sl) 2006-02-28
BR0014641A (pt) 2002-06-11
SK287058B6 (sk) 2009-10-07
JP2012121904A (ja) 2012-06-28
NO324792B1 (no) 2007-12-10
CN1189467C (zh) 2005-02-16
ATE309998T1 (de) 2005-12-15
AU777708B2 (en) 2004-10-28
AR031531A1 (es) 2003-09-24
UA74796C2 (en) 2006-02-15
BG106527A (en) 2003-02-28
CA2379575C (en) 2011-03-15
DE60024115D1 (de) 2005-12-22
PL212237B1 (pl) 2012-08-31
DE60024115T2 (de) 2006-07-27
HK1048306B (zh) 2005-06-10
ZA200201509B (en) 2003-04-30
US8012995B1 (en) 2011-09-06
WO2001023378A1 (en) 2001-04-05
TR200200789T2 (tr) 2002-08-21
EP1088821A1 (en) 2001-04-04
EE200200165A (et) 2003-04-15
CN1377347A (zh) 2002-10-30
JP5015397B2 (ja) 2012-08-29
HUP0203312A3 (en) 2003-02-28
CZ2002880A3 (cs) 2002-06-12
KR20020062282A (ko) 2002-07-25
EE05109B1 (et) 2008-12-15
NZ517424A (en) 2004-01-30
JP2003510319A (ja) 2003-03-18
IL148876A0 (en) 2002-09-12
IL148876A (en) 2010-11-30

Similar Documents

Publication Publication Date Title
EA200200417A1 (ru) Фармацевтически активные производные сульфонамида
EA200300412A1 (ru) Фармацевтически активные производные сульфонамида, содержащие как липофильные, так и ионизируемые фрагменты, в качестве ингибиторов jun-протеинкиназ
CY1110904T1 (el) Φαρμακευτικως ενεργα παραγωγα βενζοσουλφοναμιδιου ως αναστολεις πρωτεϊνικων κινασων jun
EA200200708A1 (ru) Производные бензазола и их применение в качестве модуляторов jnk
EA200100971A1 (ru) Новые соединения и композиции в качестве ингибиторов протеазы
BG66085B1 (bg) Фенилаланинови производни
EA200600364A1 (ru) Производные (тио)карбамоилциклогексана в качестве антагонистов d/dрецептора
EA200100983A1 (ru) Производные 13-метилэритромицина
DE69030315D1 (de) Kleine zyklische inhibitoren der blutplättchenaggregation
EA200600811A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ТЕТРАГИДРОСПИРО {ПИПЕРИДИН-2,7'-ПИРРОЛО [3,2-b]ПИРИДИНА} И НОВЫЕ ПРОИЗВОДНЫЕ ИНДОЛА, ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАССТРОЙСТВ, СВЯЗАННЫХ С 5-HT-РЕЦЕПТОРОМ
EA200401053A1 (ru) Оксо-азабициклические соединения
EA200000614A1 (ru) 2,3-замещенные соединения индола в качестве ингибиторов сох-2
EA200000792A2 (ru) Новые пиридиновые соединения, способ их получения и содержащие их фармацевтические композиции
EA200000431A3 (ru) Новые замещенные димерные соединения, способ их получения и фармацевтические композиции, содержащие их
EA199900135A1 (ru) Производные пиразолопиридина и их применение в качестве фармацевтического препарата
DE60011110D1 (de) Pharmazeutisch wirksame sulfonyl hydrazid-derivate
EA200100969A1 (ru) Новые соединения циклобутендиона, способ их получения и содержащие их фармацевтические композиции
EA200400049A1 (ru) Оксадиазольные и тиадиазольные производные пирролидина
EA200100597A2 (ru) Новые 1,1- и 1,2-дизамещенные циклопропановые соединения, способ их получения и содержащие их фармацевтические композиции
EA200201024A1 (ru) Фармацевтические композиции, содержащие олигосахариды, и их получение
ATE271542T1 (de) 2-thiocarbamoyloxy- und 2-carbamoyloxy-derivate von cyclopentyl-heptan(en)säure als therapeutische mittel
EA200101204A1 (ru) Новые бициклические соединения аминопиразинона, способ их получения и содержащие их фармацевтические композиции
EA199900460A1 (ru) Производные бензолсульфоамида и лекарственные средства, содержащие упомянутые производные
EA200001248A1 (ru) Новые линейные и циклические производные мочевины, способ их получения и их содержащие фармацевтические композиции
EA200100344A2 (ru) Новые циклобутаиндолкарбоксамидные производные, способ их получения и содержащие их фармацевтические композиции

Legal Events

Date Code Title Description
PC4A Registration of transfer of a eurasian patent by assignment
PD4A Registration of transfer of a eurasian patent in accordance with the succession in title
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU